Cannabinoid Hyperemesis Syndrome Associated With Compulsive Showering and Acute Kidney Injury

Srihari, Priya; Li, Mengyang; Punzell, Steven; Shebak, Shady S.; Rea, William S.

doi:10.4088/pcc.15l01847

Cited by 11 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For these case series, the following CHS pharmacologic treatments were reported as helpful: benzodiazepines (six), topical capsaicin (five), haloperidol (five), and olanzapine (one) . The 44 level‐5 case reports involved 44 patients . For these case reports, the following CHS pharmacologic treatments were reported as effective: benzodiazepines (five), metoclopramide (four), haloperidol (four), ondansetron (two), morphine (two), and topical capsaicin (two) .…”

Section: Resultsmentioning

confidence: 99%

“…78 Serotonin, or 5-hydroxytryptamine (5-HT), is a major neuroendocrine transmitter in the regulation of emesis. 77 Histamine activates neurons 70 Diazepam, haloperidol, ondansetron 5 1 Authors did not report success of specific treatments Case report 71 Promethazine, ondansetron, tramadol, chlordiazepoxide/clidinium, amitriptyline 5 1 Authors did not report success of specific treatments Case report 72 Capsaicin, metoclopramide, granisetron 5 1 Metoclopramide and granisetron ineffective, successful treatment with 0.075% capsaicin cream Case report 73 Ondansetron, lorazepam, haloperidol 5 1 Ondansetron and lorazepam ineffective; successful treatment with haloperidol Case report 74 Lorazepam, ondansetron 5 1…”

Section: Medications Ineffectivementioning

confidence: 99%

See 1 more Smart Citation

Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review

et al. 2017

View full text Add to dashboard Cite

Cannabinoid hyperemesis syndrome (CHS) has become more prevalent with increasing cannabis use. CHS is often resistant to standard antiemetics. The objective of this study is to review the current evidence for pharmacologic treatment of CHS. Medline, PsycINFO, DARE, OpenGrey, Google Scholar, and the Cochrane Library were searched from inception to February 2017. Articles were selected and reviewed independently. Evidence was graded using Oxford Center for Evidence-Based Medicine guidelines. The search resulted in 1262 articles with 63 of them eligible for inclusion (205 human subjects). There were 4 prospective level-2, 3 retrospective level-3 studies, 12 level-4 case series, and 44 level-5 case reports. Among level-2 studies (64 subjects), tricyclic antidepressants (TCAs) and lorazepam were discussed as effective long- and short-term treatments, respectively, in two studies. Ondansetron, promethazine, diphenhydramine, and opioids were also mentioned, but the authors did not comment on their efficacy. Among level-3 studies (43 subjects), one reported effective treatment with antiepileptics zonisamide and levetiracetam, but not TCAs. Another reported favorable response to morphine, ondansetron, and lorazepam but did not specify the actual number of patients receiving specific treatment. Among the level-4 case series (54 subjects), benzodiazepines, haloperidol, and capsaicin were reported as helpful. For level-5 case reports (44 subjects), benzodiazepines, metoclopramide, haloperidol, ondansetron, morphine, and capsaicin were reported as effective. Effective treatments mentioned only once included fentanyl, diazepam, promethazine, methadone, nabilone, levomepromazine, piritramide, and pantoprazole. Hot showers and baths were cited in all level-4 and -5 articles as universally effective. High-quality evidence for pharmacologic treatment of CHS is limited. Benzodiazepines, followed by haloperidol and capsaicin, were most frequently reported as effective for acute treatment, and TCAs for long-term treatment. As the prevalence of CHS increases, future prospective trials are greatly needed to evaluate and further define optimal pharmacologic treatment of patients with CHS.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Medications Ineffectivementioning

confidence: 99%

Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Alguns autores relacionam a melhora dos sintomas eméticos com a redistribuição do sangue do intestino para a pele, produzida pelo banho com água quente 2,7,14 . Foi observada melhora significativa dos sintomas quando a paciente ficava sob o chuveiro.…”

Section: Critérios Menoresunclassified

“…A SHC surge em decorrência do consumo acentuado e crônico (pelo menos um ano) de maconha 2,6,8,11,13,14 e tem como sintoma característico a compulsão por banho quente 7 .…”

Section: Introductionunclassified

See 1 more Smart Citation

Maconha e gravidez: síndrome da hiperêmese por canabinoide - Relato de caso

Justi

Laurito

Comandule

et al. 2018

J. bras. psiquiatr.

View full text Add to dashboard Cite

RESUMO Os autores relatam um caso da enfermaria psiquiátrica do Hospital Geral Santa Casa de Misericórdia de Sorocaba-SP. Paciente gestante, de 19 anos, usuária crônica de maconha que apresenta náuseas e vômitos intensos não responsivos aos antieméticos, associados a dor abdominal, agitação psicomotora e hábito compulsivo de tomar banhos quentes para alívio dos sintomas, quadro que caracteriza a SHC. Trata-se de uma síndrome rara, com efeito paradoxalmente emetogênico da maconha. É subdiagnosticada e relacionada ao uso crônico e intenso de maconha. Destacamos que não foi encontrada descrição de caso na literatura brasileira. A conclusão deste relato reporta a importância do reconhecimento e categorização da síndrome e sua correlação com a dependência de maconha, pois o tratamento implica a suspensão do uso de maconha, tratamento da dependência, além da prevenção de suas complicações clínicas.

show abstract

Cannabinoid Hyperemesis Syndrome

Bhatt

Queen

2019

Curr Emerg Hosp Med Rep

View full text Add to dashboard Cite

Purpose of Review This review describes the clinical presentation and treatment for cannabinoid hyperemesis syndrome (CHS). Typical treatment for nausea, vomiting, and abdominal pain may not be effective in patients with CHS. Alternative treatments have been suggested. Recent Findings The pathophysiology of CHS may be due to dysregulation of the endocannabinoid system. Two cannabinoid receptors (CB1, CB2) have been identified. Theories proposed to explain CHS including chronic stimulation of the CB1 receptor, binding of the CB1 receptor causing decreased gut motility, desensitization of CB1 receptors (these CB1 receptors generally have antiemetic effects), or interaction of the TRVP-1 receptor with the ennocannabinoid system. Summary CHS should be in the differential diagnosis for any patient with nausea, vomiting, and abdominal pain. The usual treatment for nausea, vomiting, and abdominal pain may not be effective for patients with CHS. Other newer, off-label treatments for CHS have been proposed. Keywords Cannabinoid hyperemesissyndrome. CHS. Chronicabdominal pain. Chronic marijuanauseand vomiting,hot shower for vomiting control, capsaicin for CHS, haloperidol for CHS This article is part of the Topical Collection on Pain Management

show abstract

Cannabinoid Hyperemesis Syndrome Associated With Compulsive Showering and Acute Kidney Injury

Cited by 11 publications

References 7 publications

Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review

Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review

Maconha e gravidez: síndrome da hiperêmese por canabinoide - Relato de caso

Cannabinoid Hyperemesis Syndrome

Contact Info

Product

Resources

About